18:29 , Apr 20, 2018 |  BC Week In Review  |  Clinical News

Celldex discontinues development of glembatumumab vedotin after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (TNBC)...
19:11 , Apr 16, 2018 |  BC Extra  |  Clinical News

Celldex routed after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) fell $1.39 (65%) to $0.76 on Monday after it said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb...
17:35 , Nov 4, 2016 |  BC Week In Review  |  Company News

Kolltan, Celldex deal

Celldex will acquire cancer company Kolltan for 19.2 million Celldex shares valued at $60.5 million based on the company's close of $3.15 on Oct. 31, the day before the deal was announced. Kolltan shareholders are...
23:22 , Nov 1, 2016 |  BC Extra  |  Company News

Celldex acquiring Kolltan

Celldex Therapeutics Inc. (NASDAQ:CLDX) will acquire cancer company Kolltan Pharmaceuticals Inc. (New Haven, Conn.) in a stock deal, including shares valued at $62.5 million up front. Kolltan shareholders are also eligible for $172.5 million in...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

KTN3379: Updated Phase I data

Updated data from 38 patients with advanced solid tumors in the 2-part, open-label, U.S. Phase I KTN3379-CL-001 trial showed that IV KTN3379 every 3 weeks plus Erbitux cetuximab led to a complete response in a...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

KTN3379: Phase Ib started

Kolltan began an open-label, U.S. Phase Ib trial to evaluate 1,000 mg IV KTN3379 every 2 weeks plus oral Zelboraf twice daily for 4-6 weeks in about 10 patients. Patients whose tumors demonstrate sufficient iodine...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

KTN3379: Phase I started

Kolltan began an open-label, U.S. Phase I trial to evaluate KTN3379 prior to surgical resection of tumor in about 29 HPV-negative and HPV-positive patients with SCCHN. Kolltan Pharmaceuticals Inc. , New Haven, Conn.   Product:...
07:00 , Jun 29, 2015 |  BC Week In Review  |  Clinical News

KTN3379: Interim Phase I data

Interim data from 36 patients with advanced solid tumors in a 2-part, open-label, U.S. Phase Ib trial showed that KTN3379 alone and in combination with Erbitux cetuximab, Zelboraf vemurafenib or Herceptin trastuzumab led to 4...
01:39 , Jan 29, 2015 |  BC Extra  |  Financial News

Kolltan withdraws IPO

Cancer play Kolltan Pharmaceuticals Inc. (New Haven, Conn.) withdrew its proposed IPO on NASDAQ. The company did not provide a reason in its SEC filing and did not respond to inquiries. In September, Kolltan filed...
01:33 , Sep 13, 2014 |  BC Extra  |  Financial News

Cancer play Kolltan files for IPO

Kolltan Pharmaceuticals Inc. (New Haven, Conn.) filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink Partners; Stifel; Guggenheim Securities; and Janney Montgomery Scott. Kolltan's KTN3379 is in Phase I...